Medications to lower a1c
Pro Research Analysisby 
Searched over 200M research papers
Medications to Lower A1C: Key Drug Classes and Their Effects
Oral Antidiabetic Agents and A1C Reduction
Oral antidiabetic agents (OADs) are widely used to lower A1C in people with type 2 diabetes. Most OADs, including biguanides (like metformin), sulfonylureas, thiazolidinediones, DPP-4 inhibitors, and others, typically lower A1C by about 0.5% to 1.25%. Thiazolidinediones and sulfonylureas are among the most effective, with average reductions of about 1.0% to 1.25%. The greatest benefit is usually seen within the first 4 to 6 months of starting therapy, and the average maximum reduction in A1C is about 1.5%. The starting A1C level can influence the amount of reduction, with higher baseline A1C predicting a greater drop.
Newer Diabetes Medications: GLP-1 Agonists, SGLT2 Inhibitors, and DPP-4 Inhibitors
Newer classes of diabetes medications also play a significant role in lowering A1C. GLP-1 receptor agonists, such as liraglutide, have shown strong effectiveness, with studies reporting reductions from an average A1C of 9.7% to 7.1%, and even greater improvements in some groups. SGLT2 inhibitors and DPP-4 inhibitors also contribute to A1C lowering, though the degree of reduction may vary. Notably, GLP-1 agonists have been linked to both A1C reduction and a lower risk of cardiovascular events, while SGLT2 and DPP-4 inhibitors have less clear effects on cardiovascular outcomes related to A1C loweringFralick2020Kashima2019.
Combination Therapy and Treatment Algorithms
Clinical guidelines recommend a stepwise approach to medication, starting with monotherapy (often metformin), and adding other agents such as sulfonylureas, GLP-1 agonists, SGLT2 inhibitors, or DPP-4 inhibitors if A1C targets are not met. Dual and triple therapy combinations are common, and insulin may be added if oral and injectable agents are insufficient. The choice of medications is based on safety, risk of hypoglycemia, efficacy, simplicity, patient adherence, and cost.
Medication Engagement and A1C Outcomes
Consistent use of prescribed diabetes medications is strongly associated with lower A1C levels. Higher medication engagement, measured by the proportion of days covered, leads to better glycemic control, regardless of the specific drug class used. Pharmacist involvement and patient-specific medication recommendations can further support A1C reductionMasuda2020Evans2021.
Continuous Glucose Monitoring (CGM) and Medication Synergy
For people with type 2 diabetes not on insulin, using a continuous glucose monitor (CGM) alongside medications such as GLP-1 agonists, sulfonylureas, or DPP-4 inhibitors can lead to additional A1C reductions. CGM use alone is associated with a modest decrease in A1C, and the combination with certain medications can enhance this effect.
Special Considerations: Falsely Low A1C Readings
Some medications and medical conditions can cause falsely low A1C readings, such as drugs that induce hemolysis (e.g., sulfasalazine, dapsone) or treatments for chronic kidney disease (iron and erythropoietin). In these cases, A1C may not accurately reflect true blood glucose control, and alternative monitoring methods like fructosamine or regular glucose checks may be neededMitchell2018Ng2010.
Conclusion
A variety of medications—including metformin, sulfonylureas, thiazolidinediones, GLP-1 agonists, SGLT2 inhibitors, and DPP-4 inhibitors—are effective in lowering A1C, especially when used in combination and with good medication adherence. The choice of therapy should be individualized, and regular monitoring is essential to ensure optimal glycemic control and to avoid misleading A1C results in certain clinical situationsSherifali2010Rodbard2009Fralick2020+5 MORE.
Sources and full results
Most relevant research papers on this topic
The Effect of Oral Antidiabetic Agents on A1C Levels
Oral antidiabetic agents show the most benefit in the first 4 to 6 months, with A1C levels unlikely to fall more than 1.5% on average, and pretreated A1C levels have a modest effect on the fall of A1C levels in response to treatment.
Drug-Induced Falsely Low A1C: Report of a Case Series From a Diabetes Clinic
Drug-induced hemolysis, most commonly due to sulfasalazine use, can cause falsely low A1C levels in patients with diabetes, affecting the accuracy of assessing glycemic control.
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.
This algorithm helps physicians manage type 2 diabetes by aiming for a hemoglobin A1c of 6.5% or less, prioritizing safety, efficacy, simplicity, patient adherence, and cost, and monitoring therapy frequently.
DOI